pembrolizumab
-
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC
Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Tri…
-
最新汇总!2020获批的PD-1/L1疗法,囊括13类癌症
本文转自:环宇达康,药时代授权转载,衷心感谢!点击阅读原文 免疫疗法是攻克癌症的希望,通过激活人体自身的免疫系统攻击癌症的方式已被证实可以用于所有的实体肿瘤,这种旨在充分利用人体自…